{"id":845740,"date":"2025-05-01T17:27:58","date_gmt":"2025-05-01T21:27:58","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/channel-therapeutics-provides-announcement-on-2024-annual-report-to-comply-with-nyse-american-listing-rules\/"},"modified":"2025-05-01T17:27:58","modified_gmt":"2025-05-01T21:27:58","slug":"channel-therapeutics-provides-announcement-on-2024-annual-report-to-comply-with-nyse-american-listing-rules","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/channel-therapeutics-provides-announcement-on-2024-annual-report-to-comply-with-nyse-american-listing-rules\/","title":{"rendered":"Channel Therapeutics Provides Announcement on 2024 Annual Report to Comply with NYSE American Listing Rules"},"content":{"rendered":"
\n

FREEHOLD, N.J., May 01, 2025 (GLOBE NEWSWIRE) — Channel Therapeutics Corporation, (\u201cChannel\u201d or the \u201cCompany\u201d), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today advises that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission on March 27, 2025, the audited financial statements contained an audit opinion from its independent registered public accounting firm that included a going concern emphasis of matter paragraph.<\/p>\n

Release of this information is required by Sections 410(h) and 610(b) of the NYSE American LLC Company Guide. This announcement does not represent any change or amendment to the Company’s consolidated financial statements or to its Annual Report on Form 10-K for the year ended December 31, 2024.<\/p>\n

\n About Channel <\/strong>\n <\/p>\n

Channel Therapeutics Corporation is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The Company\u2019s initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain and post-surgical nerve blocks. For company updates and to learn more about Channel, visit www.channeltherapeutics.com<\/a> or follow us on\u00a0social media.<\/p>\n

Channel Media and Investor Inquires:<\/p>\n

For Investor Inquiries:
Mike Moyer
Managing Director, LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

FREEHOLD, N.J., May 01, 2025 (GLOBE NEWSWIRE) — Channel Therapeutics Corporation, (\u201cChannel\u201d or the \u201cCompany\u201d), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today advises that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission on March 27, 2025, the audited financial statements contained an audit opinion from its independent registered public accounting firm that included a going concern emphasis of matter paragraph. Release of this information is required by Sections 410(h) and 610(b) of the NYSE American LLC Company Guide. This announcement does not represent any change or amendment to the Company’s consolidated financial statements or to its Annual … <\/p>\n

Continue reading “Channel Therapeutics Provides Announcement on 2024 Annual Report to Comply with NYSE American Listing Rules”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-845740","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nChannel Therapeutics Provides Announcement on 2024 Annual Report to Comply with NYSE American Listing Rules - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/channel-therapeutics-provides-announcement-on-2024-annual-report-to-comply-with-nyse-american-listing-rules\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Channel Therapeutics Provides Announcement on 2024 Annual Report to Comply with NYSE American Listing Rules - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"FREEHOLD, N.J., May 01, 2025 (GLOBE NEWSWIRE) — Channel Therapeutics Corporation, (\u201cChannel\u201d or the \u201cCompany\u201d), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today advises that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission on March 27, 2025, the audited financial statements contained an audit opinion from its independent registered public accounting firm that included a going concern emphasis of matter paragraph. Release of this information is required by Sections 410(h) and 610(b) of the NYSE American LLC Company Guide. This announcement does not represent any change or amendment to the Company’s consolidated financial statements or to its Annual … Continue reading "Channel Therapeutics Provides Announcement on 2024 Annual Report to Comply with NYSE American Listing Rules"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/channel-therapeutics-provides-announcement-on-2024-annual-report-to-comply-with-nyse-american-listing-rules\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-01T21:27:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0Mjg1MCM2OTE2NDM5IzUwMDEyNjcxOQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/channel-therapeutics-provides-announcement-on-2024-annual-report-to-comply-with-nyse-american-listing-rules\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/channel-therapeutics-provides-announcement-on-2024-annual-report-to-comply-with-nyse-american-listing-rules\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Channel Therapeutics Provides Announcement on 2024 Annual Report to Comply with NYSE American Listing Rules\",\"datePublished\":\"2025-05-01T21:27:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/channel-therapeutics-provides-announcement-on-2024-annual-report-to-comply-with-nyse-american-listing-rules\\\/\"},\"wordCount\":230,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/channel-therapeutics-provides-announcement-on-2024-annual-report-to-comply-with-nyse-american-listing-rules\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0Mjg1MCM2OTE2NDM5IzUwMDEyNjcxOQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/channel-therapeutics-provides-announcement-on-2024-annual-report-to-comply-with-nyse-american-listing-rules\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/channel-therapeutics-provides-announcement-on-2024-annual-report-to-comply-with-nyse-american-listing-rules\\\/\",\"name\":\"Channel Therapeutics Provides Announcement on 2024 Annual Report to Comply with NYSE American Listing Rules - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/channel-therapeutics-provides-announcement-on-2024-annual-report-to-comply-with-nyse-american-listing-rules\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/channel-therapeutics-provides-announcement-on-2024-annual-report-to-comply-with-nyse-american-listing-rules\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0Mjg1MCM2OTE2NDM5IzUwMDEyNjcxOQ==\",\"datePublished\":\"2025-05-01T21:27:58+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/channel-therapeutics-provides-announcement-on-2024-annual-report-to-comply-with-nyse-american-listing-rules\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/channel-therapeutics-provides-announcement-on-2024-annual-report-to-comply-with-nyse-american-listing-rules\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/channel-therapeutics-provides-announcement-on-2024-annual-report-to-comply-with-nyse-american-listing-rules\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0Mjg1MCM2OTE2NDM5IzUwMDEyNjcxOQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0Mjg1MCM2OTE2NDM5IzUwMDEyNjcxOQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/channel-therapeutics-provides-announcement-on-2024-annual-report-to-comply-with-nyse-american-listing-rules\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Channel Therapeutics Provides Announcement on 2024 Annual Report to Comply with NYSE American Listing Rules\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Channel Therapeutics Provides Announcement on 2024 Annual Report to Comply with NYSE American Listing Rules - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/channel-therapeutics-provides-announcement-on-2024-annual-report-to-comply-with-nyse-american-listing-rules\/","og_locale":"en_US","og_type":"article","og_title":"Channel Therapeutics Provides Announcement on 2024 Annual Report to Comply with NYSE American Listing Rules - Market Newsdesk","og_description":"FREEHOLD, N.J., May 01, 2025 (GLOBE NEWSWIRE) — Channel Therapeutics Corporation, (\u201cChannel\u201d or the \u201cCompany\u201d), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today advises that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission on March 27, 2025, the audited financial statements contained an audit opinion from its independent registered public accounting firm that included a going concern emphasis of matter paragraph. Release of this information is required by Sections 410(h) and 610(b) of the NYSE American LLC Company Guide. This announcement does not represent any change or amendment to the Company’s consolidated financial statements or to its Annual … Continue reading \"Channel Therapeutics Provides Announcement on 2024 Annual Report to Comply with NYSE American Listing Rules\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/channel-therapeutics-provides-announcement-on-2024-annual-report-to-comply-with-nyse-american-listing-rules\/","og_site_name":"Market Newsdesk","article_published_time":"2025-05-01T21:27:58+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0Mjg1MCM2OTE2NDM5IzUwMDEyNjcxOQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/channel-therapeutics-provides-announcement-on-2024-annual-report-to-comply-with-nyse-american-listing-rules\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/channel-therapeutics-provides-announcement-on-2024-annual-report-to-comply-with-nyse-american-listing-rules\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Channel Therapeutics Provides Announcement on 2024 Annual Report to Comply with NYSE American Listing Rules","datePublished":"2025-05-01T21:27:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/channel-therapeutics-provides-announcement-on-2024-annual-report-to-comply-with-nyse-american-listing-rules\/"},"wordCount":230,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/channel-therapeutics-provides-announcement-on-2024-annual-report-to-comply-with-nyse-american-listing-rules\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0Mjg1MCM2OTE2NDM5IzUwMDEyNjcxOQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/channel-therapeutics-provides-announcement-on-2024-annual-report-to-comply-with-nyse-american-listing-rules\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/channel-therapeutics-provides-announcement-on-2024-annual-report-to-comply-with-nyse-american-listing-rules\/","name":"Channel Therapeutics Provides Announcement on 2024 Annual Report to Comply with NYSE American Listing Rules - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/channel-therapeutics-provides-announcement-on-2024-annual-report-to-comply-with-nyse-american-listing-rules\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/channel-therapeutics-provides-announcement-on-2024-annual-report-to-comply-with-nyse-american-listing-rules\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0Mjg1MCM2OTE2NDM5IzUwMDEyNjcxOQ==","datePublished":"2025-05-01T21:27:58+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/channel-therapeutics-provides-announcement-on-2024-annual-report-to-comply-with-nyse-american-listing-rules\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/channel-therapeutics-provides-announcement-on-2024-annual-report-to-comply-with-nyse-american-listing-rules\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/channel-therapeutics-provides-announcement-on-2024-annual-report-to-comply-with-nyse-american-listing-rules\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0Mjg1MCM2OTE2NDM5IzUwMDEyNjcxOQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0Mjg1MCM2OTE2NDM5IzUwMDEyNjcxOQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/channel-therapeutics-provides-announcement-on-2024-annual-report-to-comply-with-nyse-american-listing-rules\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Channel Therapeutics Provides Announcement on 2024 Annual Report to Comply with NYSE American Listing Rules"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/845740","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=845740"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/845740\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=845740"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=845740"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=845740"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}